Delivery Order SPE2DB20D2104-SPE2DB25FMWBF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $31,805.90 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract is scheduled for ultimate completion on June 3, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $37,967.82 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in packages of 30 units. This delivery order, which is a child contract under a larger vehicle, requires completion by September 4, 2025, and was competitively awarded without set-aside provisions. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,020.92 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This firm fixed-price delivery order, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $4,644.48 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, competitively awarded on August 18, 2025, with an ultimate completion date of August 19, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $5,213.80 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by September 4, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of BIKTARVY 50-200-25 mg tablets (30-count units) with a ceiling value of $11,939.20. This competitively awarded, firm fixed-price delivery order is non-set-aside and carries an ultimate completion date of June 2, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor within the federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $23,421.82 on June 26, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, executed through competitive procedures. The contract is set to conclude on June 27, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. BIKTARVY is an HIV treatment...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $4,771.86 on August 6, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, completed under competitive procurement procedures. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 7, 2025. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) valued at $141,757, with a firm fixed price structure and no set-aside designation. The award was issued on July 30, 2025, with an ultimate completion date of July 31, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under a larger contracting vehicle supporting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units, valued at $2,232.63. This firm fixed-price delivery order, which is due for completion by August 6, 2025, represents a non-set-aside competitive award. The awardee, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMWBFDelivery Order
The Defense Logistics Agency awarded a $4,118.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. The delivery was completed by July 23, 2025, and performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This was a competitively awarded contract with no set-aside designation, reflecting the agency's standard procurement practices for pharmaceutical supplies through open competition. This delivery order was issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications and medical commodities to support military healthcare programs worldwide. The delivery of BIKTARVY, an antiretroviral medication, represents routine fulfillment of the company's obligations to provide brand-name and generic pharmaceuticals across multiple therapeutic domains to defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 7/22/25 |